New hope for hard-to-treat breast cancer: immune-boosting drug plus chemo shows promise

This study tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy can help shrink tumors or slow disease in people with advanced HER2-negative breast cancer. About 92 adults whose cancer has worsened after prior treatments will receive the combination. The goal is to see how many patients respond and how long the benefit lasts.